Observational studyCardiovascular diabetology2020
Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes.
Observational study in Cardiovascular diabetology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- A Composite Score of Insulin Resistance and Inflammation Biomarkers for Predicting Lower Limb Complications in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2025Article
- Visit-to-visit glucose variability is associated with echocardiographic variables in people with type 2 diabetes: epidemiological and mendelian randomization approaches.Diabetology & metabolic syndrome · 2025Article
- Article
- Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus.Scientific reports · 2024Article
- Association of carotid atherosclerosis markers with all-cause and cardiovascular disease-specific mortality in persons with type 2 diabetes: a causal mediation analysis with glucose variation.Acta diabetologica · 2024Article
- Visit to Visit Hemoglobin A1c Variation and Long-term Risk of Major Adverse Limb Events in Patients With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2023Article
- Long-Term Visit-to-Visit Glycemic Variability as a Predictor of Major Adverse Limb and Cardiovascular Events in Patients With Diabetes.Journal of the American Heart Association · 2023Article
- Correlation Between Glycemic Variability and Diabetic Complications: A Narrative Review.International journal of general medicine · 2023Review
- Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients with Peripheral Arterial Disease.International journal of molecular sciences · 2022Review
- Endothelial Dysfunction and Platelet Hyperactivation in Diabetic Complications Induced by Glycemic Variability.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2022Review
- Association of time in range with lower extremity atherosclerotic disease in type 2 diabetes mellitus: a prospective cohort study.Endocrine · 2022Article
- Significance of Glycemic Variability in Diabetes Mellitus.Internal medicine (Tokyo, Japan) · 2022Article
- Implications of fasting plasma glucose variability on the risk of incident peripheral artery disease in a population without diabetes: a nationwide population-based cohort study.Cardiovascular diabetology · 2022Article
- Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies.International journal of molecular sciences · 2021Review
- Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications.Cardiovascular diabetology · 2021Review
- Variability in Annual Fasting Glucose and the Risk of Peripheral Artery Disease in Patients with Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.Pharmacology & therapeutics · 2020Review
- Serum malondialdehyde-modified low-density lipoprotein level is a risk factor for peripheral artery disease in patients with stage 3 to 5 chronic kidney disease.Tzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated whether visit-to-visit fasting plasma glucose (FPG) variability, as measured by the coefficient of variation (CV), increased peripheral artery disease (PAD) risk.
methodsIndividuals with type 2 diabetes from the National Diabetes Care Management Program during the period 2002-2004, ≥ 30 years of age, and free of PAD (n = 30,932) were included and monitored until 2011. Cox proportional hazards regression models were implemented to analyze related determinants of PAD.
resultsA total of 894 incident cases of PAD were identified during an average 8.2 years of follow-up, resulting in a crude incidence rate of 3.53 per 1000 person-years. Both FPG-CV and HbA1c were significantly associated with PAD after multivariate adjustment, with corresponding hazard ratios of 1.24 [95% confidence interval (CI) 1.04-1.47] for FPG-CV in the third tertile and 1.50 (95% CI 1.10-2.04) for HbA1c ≥ 10%. The findings of the sensitivity analysis remained consistent after excluding potential confounders, demonstrating the consistency of the results.
conclusionsThe associations between HbA1c, variability in FPG-CV, and PAD suggest a linked pathophysiological mechanism, suggesting the crucial role of glycemic variability in clinical management and therapeutic goals in preventing PAD in type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.